Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis
Cancer Immunology, Immunotherapy · 06.04.2026 · 75 (5)
DOI: 10.1007/s00262-026-04382-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 06.04.2026. Verfasst von Junjie Hang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Ac…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Scientific Research Foundation of Guangdong Province, Cooperation Fund of CHCAMS and SZCH, Project funded by Wu Jieping Medical Foundation.
Abstract (Originalsprache)
Background
The optimal sequence of administering immune checkpoint inhibitors (ICIs) and chemotherapy in advanced esophageal cancer (EC) and gastric cancer (GC) remains to be established. Understanding how this sequencing affects overall survival (OS) is crucial for optimizing treatment strategies.
Methods
This multicenter study enrolled 334 patients diagnosed with advanced EC or GC between January 2018 and October 2024. To reduce confounding biases, propensity score matching (PSM) was applied, resulting in 292 matched patients categorized into two groups, including those receiving ICIs first (IF) and those receiving chemotherapy first (CF).
Results
Following PSM, Kaplan–Meier analysis showed that the CF group had a significantly prolonged median OS compared to the IF group (16.80 vs. 14.60 months; p = 0.014). These findings were further corroborated in the unmatched cohort (16.60 vs. 14.60 months; p = 0.012). Multivariable analysis identified ECOG performance status, PD-L1 expression, antibiotic use, and line of ICI treatment as independent prognostic factors, whereas the i mmunochemotherapy administration sequence did not retain independent prognostic significance. Subgroup analysis revealed that among patients receiving first-line immunochemotherapy, those in the CF group had significantly longer OS (16.50 vs. 12.30 months; p = 0.004), with no significant difference observed for those beyond first-line treatment ( p = 0.862). The objective response rate and disease control rate were comparable between the two groups.
Conclusions
This study suggests that administering chemotherapy prior to immunotherapy appears to improve OS in patients with advanced EC and GC, particularly when initiated as first-line treatment. These findings highlight the need for further research into biomarkers and personalized treatment strategies to enhance patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen,…
- Shanghai JingAn District ZhaBei Central Hospital, Shanghai, 200070, China.
- The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, 213000, China.
- Nanchuan Hospital Affiliated to Chongqing Medical University/The People's Hospital of Nanchuan Chongqing, Chongqing, 408400, Nanchuan, China.
- JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
- Centre for Health Education and Health Promotion, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China.
Förderung
- Medical Scientific Research Foundation of Guangdong Province
- Cooperation Fund of CHCAMS and SZCH
- Project funded by Wu Jieping Medical Foundation
- the Foundation Sponsored by National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical…
- Science, Technology and Innovation Commission of Shenzhen Municipality (STIC)
- Jing'an District Outstanding Youth Program Project
- Anhui Provincial Health Scientific Research Project
- Shenzhen Key Medical Discipline Construction Fund
Zitieren
APA
Hang, J., Wu, L., Xiao, L., Duan, Q., Zhao, H., Huang, J., Guo, J., Huang, Y., Zhang, D., Cheng, G., Dong, X., Xue, P., & Chang, J. (2026). Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis. Cancer Immunology, Immunotherapy, 75(5). https://doi.org/10.1007/s00262-026-04382-3
Vancouver
Hang J, Wu L, Xiao L, Duan Q, Zhao H, Huang J, et al. Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis. Cancer Immunology, Immunotherapy. 2026;75(5). doi:10.1007/s00262-026-04382-3
BibTeX
@article{Hang2026,
author = {Hang, Junjie and Wu, Lixia and Xiao, Li and Duan, Qiuhua and Zhao, Han and Huang, Junjie and Guo, Jinfeng and Huang, Yiqing and Zhang, Dapeng and Cheng, Gang and Dong, Xiao and Xue, Peng and Chang, Jianhua},
title = {Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysis},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
volume = {75},
number = {5},
doi = {10.1007/s00262-026-04382-3}
}
EUVIMED